Immunotherapy has meaningfully improved survival for esophageal cancer, though success rates vary widely depending on the stage of disease, the type of esophageal cancer, and a key biomarker called PD-L1. When combined with chemotherapy as a first-line treatment for advanced disease, immunotherapy extends median overall survival to roughly 13 to 15 months, compared to about 9 to 11 months with chemotherapy alone. For patients treated with surgery after initial therapy, adjuvant immunotherapy doubles the time before cancer returns.
How Immunotherapy Is Used Across Stages
Immunotherapy now plays a role at multiple points in esophageal cancer treatment. Before surgery (the neoadjuvant setting), it can be combined with chemotherapy or chemoradiation to shrink tumors and improve surgical outcomes. After surgery (the adjuvant setting), it helps prevent recurrence. And for advanced or metastatic cancer that can’t be removed surgically, it serves as a core part of first-line treatment alongside chemotherapy.
The FDA has approved three immunotherapy drugs for esophageal cancer: pembrolizumab, nivolumab, and tislelizumab. All three are immune checkpoint inhibitors that work by blocking a protein called PD-1, which cancer cells exploit to hide from the immune system. Removing that shield allows the body’s own immune cells to recognize and attack the tumor.
Survival With Advanced Esophageal Cancer
The most robust survival data comes from CheckMate 648, a trial of 970 patients with advanced esophageal squamous cell carcinoma. Adding nivolumab to chemotherapy increased median overall survival from 10.7 months to 13.2 months across all patients. For those whose tumors tested positive for PD-L1 (a protein that predicts how well immunotherapy will work), the gap was even larger: 15.4 months versus 9.1 months.
A dual-immunotherapy approach, combining nivolumab with ipilimumab instead of chemotherapy, also outperformed chemotherapy alone in PD-L1-positive patients, with median survival of 13.7 months compared to 9.1 months. This gives oncologists two viable immunotherapy strategies depending on a patient’s overall health and tumor profile.
After Surgery: Preventing Recurrence
For patients who undergo chemoradiation followed by surgery, the CheckMate 577 trial showed that continuing with nivolumab afterward roughly doubled disease-free survival. Patients receiving immunotherapy went a median of 22.4 months before their cancer returned, compared to 11.0 months for those on placebo. That’s an additional 11 months, on average, of living without detectable disease.
The benefit was strongest in squamous cell carcinoma, where disease-free survival reached 29.7 months. Patients with adenocarcinoma also benefited, with disease-free survival of 19.4 months on nivolumab versus 11.1 months on placebo.
Squamous Cell vs. Adenocarcinoma
Esophageal cancer comes in two main types, and they don’t respond equally to immunotherapy. Squamous cell carcinoma, which forms in the upper and middle esophagus, tends to have higher levels of PD-L1 expression, making it a better target for checkpoint inhibitors. Adenocarcinoma, which develops in the lower esophagus near the stomach, typically has lower PD-L1 levels but higher rates of other molecular changes.
Before surgery, adding immunotherapy to chemotherapy or chemoradiation produces a complete pathologic response (meaning no detectable cancer in the surgical specimen) in roughly 14% to 56% of squamous cell carcinoma patients, depending on the specific drug combination. The highest rate, 55.6%, came from a trial combining pembrolizumab with chemoradiation. For adenocarcinoma, the data is more limited, with one trial reporting complete pathologic response in about 25% to 40% of patients.
PD-L1 Score Predicts Who Benefits Most
Not everyone responds equally to immunotherapy, and the single strongest predictor of benefit is PD-L1 expression, measured using a Combined Positive Score (CPS). This score reflects how much PD-L1 protein is present in and around the tumor. The higher the score, the more likely immunotherapy will help.
A meta-analysis of seven large trials found that benefit increases in a consistent, linear pattern with higher CPS scores. Patients with a CPS of 10 or above saw the greatest improvement in survival, tumor shrinkage, and time before the disease progressed. Those with a CPS between 5 and 9 still saw meaningful gains. Below a CPS of 5, the survival benefit becomes less certain, though some patients in the 1 to 4 range still respond. For patients with a CPS below 1, meaning virtually no PD-L1 expression, immunotherapy did not produce a statistically significant survival benefit.
A CPS of 5 or higher appears to be the practical threshold where immunotherapy’s benefits most clearly outweigh its risks. Your oncologist will test your tumor’s PD-L1 status before recommending treatment, and this score will be a central factor in the decision.
Adding Radiation to Immunotherapy
For patients with recurrent or metastatic esophageal cancer already receiving immunotherapy and chemotherapy, adding radiation therapy may further improve outcomes. A matched study of 128 patients found that those who received radiation alongside chemoimmunotherapy survived a median of 23.7 months, compared to 13.0 months for those on chemoimmunotherapy alone. Progression-free survival also improved, from 7.3 months to 10.4 months. No treatment-related deaths occurred in either group, suggesting the combination is tolerable for most patients.
What These Numbers Mean in Practice
Median survival figures describe the point at which half of patients are still alive, meaning many patients live considerably longer than the median, and some shorter. Immunotherapy has a distinctive response pattern compared to chemotherapy: it takes longer to start working in some cases, but when it does work, the responses can be durable. A subset of patients experience what oncologists call a “tail on the curve,” where their disease remains controlled for years rather than months.
The practical takeaway is that immunotherapy has become standard care for most esophageal cancer patients, not a last resort. It is most effective for squamous cell carcinoma with high PD-L1 expression, but it also benefits many adenocarcinoma patients and those with moderate PD-L1 scores. Combined with chemotherapy, surgery, or radiation at different stages, it has extended survival at every point in the treatment pathway where it has been tested.